Drug Repurposing for Metabolic-Associated Fatty Liver Disease: Current Evidence, Challenges, and Future Perspectives
Xiaonan Liang, Ping Jin, Yan Xue, Yongliang Jia, Hongmei Zhu, Guiyi Gong, Hua Zhou, Hao Hu, Simon Ming-Yuen Lee · 2026
Read Drug Repurposing for Metabolic-Associated Fatty Liver Disease: Current Evidence, Challenges, and Future Perspectives by Xiaonan Liang, Ping Jin, Yan Xue, Yongliang Jia, Hongmei Zhu, Guiyi Gong, Hua Zhou, Hao Hu, Simon Ming-Yuen Lee (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13588130.txt.
Description
Xiaonan Liang and co-authors grade the attempts to treat fatty liver disease with drugs borrowed from other diseases, in a 2026 review. The condition is common and short on approved medicines. Repurposing promises a shortcut, since borrowed drugs carry known safety records. The review appraises the strategies behind the candidates: real-world data mining, computer screening, and bench checks, searching trials and literature to October 2025.
For all the predictions, few candidates have reached late-stage trials, and approvals through repurposing are rarer still. The named obstacles are patient variety, missing biomarkers, mixed trial endpoints, and unproven targets. The authors back a shift to mechanism-first thinking, joining multi-layer molecular data and AI screening with living-system tests and adaptive trials. Their map is aimed at funders and trial designers.
Catalog record
| CREATOR | Xiaonan Liang, Ping Jin, Yan Xue, Yongliang Jia, Hongmei Zhu, Guiyi Gong, Hua Zhou, Hao Hu, Simon Ming-Yuen Lee |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |